Loading insider details...
Beta
Latest Form 4 (Sep 8, 2026): Exercise/Conversion of 784,314 IRD shares, $902.0K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Opus Genetics, Inc. (IRD) | Exercise/Conversion | 784,314 | $902.0K |
| Apr 22, 2026 | Opus Genetics, Inc. (IRD) | Grant/Award | 24,367 | n/a |
| Jan 8, 2026 | Opus Genetics, Inc. (IRD) | Grant/Award | 67,000 | n/a |
| Dec 31, 2025 | Opus Genetics, Inc. (IRD) | Purchase | 81,000 | $160.3K |
| Aug 27, 2025 | Opus Genetics, Inc. (IRD) | Grant/Award | 869,565 | $1000.0K |
| May 2, 2025 | Opus Genetics, Inc. (IRD) | Grant/Award | 79,504 | n/a |
| Mar 26, 2025 | Opus Genetics, Inc. (IRD) | Grant/Award | 784,314 | n/a |
| Jun 13, 2024 | Ocuphire Pharma, Inc. (OCUP) | Grant/Award | 41,143 | n/a |
| May 31, 2024 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale | 9,597 | $115.0K |
| Feb 13, 2024 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale | 1,173 | $13.4K |